ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...

IRIS Pharma becomes a subsidiary of ABIONYX Pharma and remains independent in its service activities for major pharmaceutical and biotech companies in the ophthalmology sector A potential

Related Keywords

United States ,France ,French ,America ,Jean Louis Dasseux ,Luc Demarre ,Yann Quentric ,Pierre Paul Elena ,Arthur Rouill ,Iris Pharma ,Cyrille Tupin ,Christian Chavy ,Louis Victor Delouvrier ,M Emmanuel Huynh ,Sadok Belmokhtar ,Pharma Holding ,Iris Pharma Holding ,Euronext ,Fully Compensated ,New Shares ,Commercial Court ,General Meeting ,Registration Document ,North America ,Victor Delouvrier ,Abionyx ,Dharma ,Nnounces ,Completion ,Contribution ,Wind ,Company ,Capital ,Iris ,Molding ,Bully ,Decompensated ,Issue ,Hares ,Price ,Phare ,Become ,Specialist ,Bioproducts ,